The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune astrocytopathies characterized by predominant involvement of the optic nerves and spinal cord. In most patients, an IgG autoantibody binding to astrocytic aquaporin 4, the principal water channel of the central nervous system, is detected. Rituximab, a chimeric monoclonal antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a first-line off-label treatment for patients with NMOSDs. OBJECTIVE: To perform a systematic review and a meta-analysis of the efficacy and safety of rituximab use in NMOSDs, considering the potential predictive factors related to patient response to rituximab in this disease. EVIDENCE REVIEW: English-language studies published between January 1, 2000, and July 31, 2015, were searched in the MEDLINE, Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov databases. Patient characteristics, outcome measures, treatment regimens, and recorded adverse effects were extracted. FINDINGS: Forty-six studies were included in the systematic review. Twenty-five studies that included 2 or more patients with NMOSDs treated with rituximab were included in the meta-analysis. Differences in the annualized relapse rate ratio and Expanded Disability Status Scale score before and after rituximab therapy were the main efficacy measures. Safety outcomes included the proportion of deaths, withdrawals because of toxic effects, and adverse effects. RESULTS: Among 46 studies involving 438 patients (381 female and 56 male [sex was not specified in 1 patient]; mean age at the outset of treatment, 32 years [age range, 2-77 years]), rituximab therapy resulted in a mean (SE) 0.79 (0.15) (95% CI, -1.08 to -0.49) reduction in the mean annualized relapse rate ratio and a mean (SE) 0.64 (0.27) (95% CI, -1.18 to -0.10) reduction in the mean Expanded Disability Status Scale score. A significant correlation was observed between disease duration and the Expanded Disability Status Scale score. Adverse effects were recorded in 114 of 438 (26%) patients treated with rituximab. Specifically, 45 patients (10.3%) experienced infusion-related adverse effects, 40 patients (9.1%) had an infection, 20 patients (4.6%) developed persistent leukopenia, 2 patients (0.5%) were diagnosed as having posterior reversible encephalopathy, and 7 patients (1.6%) died. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis provides evidence that rituximab therapy reduces the frequency of NMOSD relapses and neurological disability in patients with NMOSDs. However, the safety profile suggests caution in prescribing rituximab as a first-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 585
Treatment of Neuromyelitis Optica With Rituximab
Jacob, A., Weinshenker, B. G., Violich, I., McLinskey, N., Krupp, L., Fox, R. J., Wingerchuk, D. M., Boggild, M., Constantinescu, C. S., Miller, A., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 460
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul‐Enein, F., Waters, P. J., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A. C., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 433
NMO-IgG predicts the outcome of recurrent optic neuritis
Matiello, M., Lennon, V. A., Jacob, A., Pittock, S. J., Lucchinetti, C. F., Wingerchuk, D. M., & Weinshenker, B. G. (2008) · Neurology · doi:10.1212/01.wnl.0000303817.82134.da · Cited by 364
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Dale, R. C., Brilot, F., Duffy, L. V., Twilt, M., Waldman, A. T., Narula, S., Muscal, E., Deiva, K., Andersen, E., Eyre, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000570 · Cited by 347
Research works printed but not linked: 1
- Tosello B, Halbert C, Mancini J, Chabrol B, Boucraut J, Milh M. Neuromyelitis optica in children: two case reports [in French]. Arch Pediatr. 2012;19(8):827-831.
Cited by
Sorted by citations
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 503
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 376
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
Contentti, E. C., & Correale, J. D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02249-1 · Cited by 363
Sechi, E., Cacciaguerra, L., Chen, J. J.-W., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.885218 · Cited by 352
Autoantibodies in neurological disease
Prüß, H. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00543-w · Cited by 335
Treatment strategies for autoimmune encephalitis
Shin, Y., Lee, S., Park, K., Jung, K., Jung, K., Lee, S. K., & Chu, K. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 272
Kümpfel, T., Giglhuber, K., Aktaş, O., Ayzenberg, I., Bellmann–Strobl, J., Häußler, V., Havla, J. B., Hellwig, K., Hümmert, M. W., Jarius, S., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11910-z · Cited by 263
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00888 · Cited by 227
Rituximab for the treatment of multiple sclerosis: a review
Chisari, C. G., Sgarlata, E., Arena, S., Toscano, S., Luca, M., & Patti, F. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10362-z · Cited by 209
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
“Off-label use in autoimmune disease includes multiple sclerosis (360, 361), thrombotic thrombocytopenic purpura (362, 363), immune thrombocytopenia (ITP) (364), myasthenia gravis (365), neuromyelitis optica (366), lupus nephritis (367), idiopathic membranous nephropathy (368), autoimmune hemolytic anemia (369), and ch…”
BackgroundTreatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
Whittam, D. H., Cobo‐Calvo, Á., Lopez-Chiriboga, A. S., Pardo, S., Gornall, M., Cicconi, S., Brandt, A. U., Berek, K., Berger, T., Jelčić, I., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102251 · Cited by 184
“The largest meta-analysis of 46 NMOSD studies, including 438 predominantly AQP4-IgG positive patients, calculated a 79% reduction in relapse rate [Damato et al., 2016].”
BackgroundDurozard, P., Rico, A., Boutière, C., Maarouf, A., Lacroix, R., Cointe, S., Fritz, S., Brunet, C., Pelletier, J., Marignier, R., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25648 · Cited by 168
Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Cobo‐Calvo, Á., Sepúlveda, M., Rollot, F., Armangué, T., Ruiz, A., Maillart, É., Papeix, C., Audoin, B., Zéphir, H., Biotti, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1525-1 · Cited by 160
Bruijstens, A. L., Wendel, E., Lechner, C., Bartels, F., Finke, C., Breu, M., Flet‐Berliac, L., de Chalus, A., Adamsbaum, C., Capobianco, M. A. N., et al. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.10.005 · Cited by 160
New therapies for neuromyelitis optica spectrum disorder
Levy, M., Fujihara, K., & Palace, J. A. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30392-6 · Cited by 151
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
Aktaş, O., Smith, M., Rees, W. A., Bennett, J. L., She, D., Katz, E., Cree, B., & the N‐MOmentum scientific group and the N‐MOmentum study investigators (2021) · Annals of Neurology · doi:10.1002/ana.26067 · Cited by 147
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials
Pittock, S. J., Ζεκερίδου, Α., & Weinshenker, B. G. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00568-8 · Cited by 148
Barreras, P., Vasileiou, E. S., Filippatou, A. G., Fitzgerald, K. C., Levy, M., Pardo, C. A., Newsome, S. D., Mowry, E. M., Calabresi, P. A., & Sotirchos, E. S. (2022) · Neurology · doi:10.1212/wnl.0000000000201260 · Cited by 123
Wilson, R., Makuch, M., Kienzler, A., Varley, J. A., Taylor, J., Woodhall, M. R., Palace, J. A., Leite, M. I., Waters, P. J., & Irani, S. R. (2018) · Brain · doi:10.1093/brain/awy010 · Cited by 123
“Furthermore, circulating ASCs often downregulate CD20 and are, therefore, relatively insensitive to rituximab, an effective treatment for NMOSD (Damato et al., 2016).”
BackgroundThe B cell immunobiology that underlies CNS autoantibody-mediated diseases
Sun, B., Ramberger, M., O’Connor, K. C., Bashford-Rogers, R. J. M., & Irani, S. R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0381-z · Cited by 115
Häusler, D., Häusser‐Kinzel, S., Feldmann, L., Torke, S., Lepennetier, G., Bernard, C. C. A., Zamvil, S. S., Brück, W., Lehmann‐Horn, K., & Weber, M. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810470115 · Cited by 133
Serious safety events in rituximab‐treated multiple sclerosis and related disorders
Vollmer, B. L., Wallach, A. I., Corboy, J. R., Dubovskaya, K., Álvarez, E., & Kister, I. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51136 · Cited by 105
Rituximab in neurological disease: principles, evidence and practice
Whittam, D. H., Tallantyre, E. C., Jolles, S. R. A., Huda, S., Moots, R. J., Kim, H. J., Robertson, N. P., Cree, B., & Jacob, A. (2018) · Practical Neurology · doi:10.1136/practneurol-2018-001899 · Cited by 102
“Neuromyelitis optica spectrum disorders Maintenance therapy for relapse prevention Predominantly retrospective case series (of more than 400 patients in total), which consistently show a marked benefit.(13) Second-line therapy for patients that relapse despite adequate treatment with azathioprine or mycophenolate mofe…”
InfluentialEfficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis
Nepal, G., Shing, Y. K., Yadav, J. K., Rehrig, J. H., Ojha, R., Huang, D., & Gajurel, B. P. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13291 · Cited by 87
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Marcinnò, A., Marnetto, F., Valentino, P., Martire, S., Balbo, A., Drago, A., Leto, M., Capobianco, M. A. N., Panzica, G., & Bertolotto, A. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000498 · Cited by 86
Contentti, E. C., Rojas, J. I., Cristiano, E., Marques, V. D., Flores-Rivera, J. D. J., Lana–Peixoto, M. A., Navas, C., Alvarenga, R. M. P., Sato, D. K., de Castillo, I. S., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102428 · Cited by 89
Monitoring B-cell repopulation after depletion therapy in neurologic patients
Ellwardt, E., Ellwardt, L., Bittner, S., & Zipp, F. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000463 · Cited by 85
Lopez, J. A., Denkova, M., Ramanathan, S., Dale, R. C., & Brilot, F. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1316 · Cited by 79
Saggau, C., Bacher, P., Esser, D., Rasa, M., Meise, S., Mohr, N., Kohlstedt, N., Hutloff, A., Schacht, S.-S., Dargvainiene, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.005 · Cited by 79
Zhang, C., Tian, D., Yang, C., Han, B., Wang, J., Yang, L., & Shi, F. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1336 · Cited by 72
Espiritu, A. I., & Pasco, P. M. D. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.05.011 · Cited by 68
Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
Sher, E. K., Ćosović, A., Džidić-Krivić, A., Farhat, E. K., Pinjić, E., & Sher, F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121531 · Cited by 67
“Defective tolerance of central B cells has been observed in many patients with autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and others [71].”
Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases
Ran, Z., Luo, Y., Qiu-Ming, Z., & Yang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01884 · Cited by 66
Damato, V., Theorell, J., Al‐Diwani, A., Kienzler, A., Makuch, M., Sun, B., Handel, A. E., Akdeniz, D., Berretta, A., Ramanathan, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121804119 · Cited by 63
Self-citationMa, X., Kermode, A. G., Hu, X., & Qiu, W. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102522 · Cited by 63
B cell depletion in the treatment of multiple sclerosis
Myhr, K., Torkildsen, Ø., Lossius, A., Bø, L., & Holmøy, T. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1568407 · Cited by 64
“Long-term observation of rituximab therapy in rheumatoid arthritis and off label therapy in NMOSD suggests that the drug is highly effective, safe and well tolerated, but carefully monitoring is needed [29,63,92].”
BackgroundRecommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Ciron, J., Audoin, B., Bourre, B., Brassat, D., Durand‐Dubief, F., Laplaud, D. A., Maillart, É., Papeix, C., Vukusic, S., Zéphir, H., et al. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2017.11.005 · Cited by 61
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Collongues, N., Ayme‐Dietrich, E., Monassier, L., & Seze, J. D. (2019) · Drugs · doi:10.1007/s40265-018-1039-7 · Cited by 60
Treatment of Neuromyelitis Optica Spectrum Disorders
Chan, K., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168638 · Cited by 67
“Individual NMOSD patients with an early and late repopulation of B cells after rituximab therapy were observed [81].”
BackgroundInfluentialThe changing landscape of optic neuritis: a narrative review
Lott, L. B. D., Bennett, J. L., & Costello, F. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10352-1 · Cited by 61
Gospe, S. M., Chen, J. J.-W., & Bhatti, M. T. (2020) · Eye · doi:10.1038/s41433-020-01334-8 · Cited by 60
Neurological Disease in Lupus: Toward a Personalized Medicine Approach
McGlasson, S. L., Wiseman, S. J., Wardlaw, J. M., Dhaun, N., & Hunt, D. P. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01146 · Cited by 59
Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)
Li, X., Tian, D., Fan, M., Xiu, Y., Wang, X., Li, T., Jia, D., Xu, W., Song, T., Shi, F., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102325 · Cited by 62
Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
On behalf of Francophone Society of Multiple Sclerosis and OFSEP investigators, Cabre, P., Mejdoubi, M., Jeannin, S., Merle, H., Plumelle, Y., Cavillon, G., Smadja, D., & Marignier, R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8771-5 · Cited by 54
Damato, V., Balint, B., Kienzler, A., & Irani, S. R. (2018) · Movement Disorders · doi:10.1002/mds.27446 · Cited by 54
“Although immunotherapy efficacy has not been explored alongside a placebo arm, to date it appears that rituximab, azathioprine, and mycophenolate mofetil all reduce relapse rates by around 60% to 70%.(75,76) Furthermore, the avoidance of several agents with proven efficacy in multiple sclerosis is important in NMOSD a…”
BackgroundSelf-citationFlanagan, E. P., Levy, M., Katz, E., Cimbora, D. M., Drappa, J., Mealy, M. A., She, D., & Cree, B. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103352 · Cited by 53
Piga, M., Chessa, E., Peltz, M. T., Floris, A., Mathieu, A., & Cauli, A. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.01.011 · Cited by 53
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
Jalkh, G., Nahed, R. A., Macaron, G., & Rensel, M. R. (2020) · Vaccines · doi:10.3390/vaccines9010012 · Cited by 55
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease
Zhang, C., Zhang, T., Liu, Y., Jia, D., Zeng, P., Chen, D., Yuan, M., Liu, Q., Wang, Y., & Shi, F. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001070 · Cited by 52
Zhao, C., Pu, M., Chen, D., Shi, J. L., Li, Z., Guo, J., & Zhang, G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.736190 · Cited by 51
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD
Redenbaugh, V., & Flanagan, E. P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01206-x · Cited by 50
Borisow, N., Hellwig, K., & Paul, F. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0143-9 · Cited by 50
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
Brod, S. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102538 · Cited by 48
Targeting B cells to modify MS, NMOSD, and MOGAD
Graf, J., Mareš, J., Barnett, M. H., Aktaş, O., Albrecht, P., Zamvil, S. S., & Hartung, H.-P. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000919 · Cited by 48
Peters, J., & Longbrake, E. E. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104400 · Cited by 51
Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder
Kim, S., Hyun, J., & Kim, H. J. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.11.022 · Cited by 47
Treatment of neuromyelitis optica spectrum disorders
Romeo, A. R., & Segal, B. M. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000603 · Cited by 47
Chang, V. T. W., & Chang, H. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12574 · Cited by 52
Investigational drugs in development to prevent neuromyelitis optica relapses
Paul, F., Murphy, O. C., Pardo, S., & Levy, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1443077 · Cited by 46
Nepal, G., Kharel, S., Coghlan, M. A., Rayamajhi, P., & Ojha, R. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577812 · Cited by 45
Marignier, R., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G., Green, A., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000978 · Cited by 44
Lebrun‐Frénay, C., Cohen, M., Rosenthal‐Allieri, M. A., Bresch, S., Benzaken, S., Marignier, R., Seitz‐Polski, B., & Ticchioni, M. (2018) · Neurology and Therapy · doi:10.1007/s40120-018-0101-4 · Cited by 43
Takai, Y., Kuroda, H., Misu, T., Akaishi, T., Nakashima, I., Takahashi, T., Nishiyama, S., Fujihara, K., & Aoki, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102750 · Cited by 43
de Bruijn, M. A. A. M., Leypoldt, F., Dalmau, J. O., Lee, S., Honnorat, J., Clardy, S. L., Irani, S. R., Easton, A., Kunchok, A. C., & Titulaer, M. J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00650-1 · Cited by 44
Kunchok, A. C., Malpas, C. B., Nytrová, P., Havrdová, E., Alroughani, R., Terzi, M., Yamout, B., Hor, J. Y., Karabudak, R., Boz, C., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101868 · Cited by 42
Neuromyelitis optica and neuromyelitis optica spectrum disorders
Marignier, R., Cobo Calvo, A., & Vukusic, S. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000455 · Cited by 45
Approach to optic neuritis: An update
Phuljhele, S., Kedar, S., & Saxena, R. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3415_20 · Cited by 44
“[94] Eculizumab is the first monoclonal antibody that has been approved by FDA for use in NMOSD.”
BackgroundPalace, J. A., Wingerchuk, D. M., Fujihara, K., Berthele, A., Oreja‐Guevara, C., Kim, H. J., Nakashima, I., Levy, M., Terzi, M., Totolyan, N. A., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102641 · Cited by 41
Wang, Y., Chang, H., Zhang, X., & Yin, L. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102843 · Cited by 41
Spagni, G., Sun, B., Monte, G., Sechi, E., Iorio, R., Evoli, A., & Damato, V. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330086 · Cited by 39
Self-citationGhezzi, A., Banwell, B., Bar‐Or, A., Chitnis, T., Dale, R. C., Gorman, M., Kornek, B., Krupp, L., Krysko, K. M., Nosadini, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520932798 · Cited by 39
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
Wallach, A. I., Tremblay, M. A., & Kister, I. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.09.003 · Cited by 38
“2 points.(31) Possibly, even more impressive results could be achieved if all patients are treated to complete suppression of CD191 (<0.”
BackgroundAdverse Events in NMOSD Therapy
Giglhuber, K., & Berthele, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084154 · Cited by 38
Neuromyelitis Optica Spectrum Disorders
Costello, F. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001168 · Cited by 38
Shaygannejad, V., Fayyazi, E., Badihian, S., Mirmosayyeb, O., Manouchehri, N., Ashtari, F., & Asgari, N. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09180-9 · Cited by 37
Hoshino, Y., Noto, D., Sano, S., Tomizawa, Y., Yokoyama, K., Hattori, N., & Miyake, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02375-w · Cited by 36
Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab
Li, T., Zhang, L., Zhang, Q., Yang, C., Zhang, C., Li, Y.-J., Shi, F., & Li, Y. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.12.021 · Cited by 35
Novi, G., Bovis, F., Capobianco, M. A. N., Frau, J., Mataluni, G., Curti, E., Zuliani, L., Cavalla, P., Brambilla, L., Annovazzi, P. O. L., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101430 · Cited by 35
Emerging therapeutic targets for neuromyelitis optica spectrum disorder
Tradtrantip, L., Asavapanumas, N., & Verkman, A. S. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1732927 · Cited by 35
Xue, T., Yang, Y., Lu, Q., Gao, B., Chen, Z., & Wang, Z. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102166 · Cited by 33
Huang, W., Wang, L., Xia, J., Li, W., Wang, M., Yu, J. Y., Li, Q., Wang, B., Pan, J., Du, L., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15355 · Cited by 32
Tahara, M., Oeda, T., Okada, K., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Nakashima, I., Misu, T., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103730 · Cited by 29
Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155
Li, J., Xiang, Y., Li, S., Zhang, F., Ruan, X., & Guo, S. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577280 · Cited by 28
Lotan, I., McGowan, R., & Levy, M. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429010825 · Cited by 27
“A similar trend of better treatment effect in AQP-4 positive patients has been observed for other therapeutic agents, including rituximab [95], eculizumab [96], and inebilizumab [97].”
BackgroundBruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
Liu, Y., Huang, Z., Zhang, T., Han, B., Yang, G., Jia, D., Yang, L., Liu, Q., Lau, A. Y. L., Paul, F., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02997-2 · Cited by 29
Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder
Lin, J., Li, X., Xue, B., Tong, Q., Chen, Z., Zhu, W., Li, J., & Xia, J. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.02.004 · Cited by 26
Konitsioti, A., Prüß, H., Laurent, S. A., Fink, G. R., Heesen, C., & Warnke, C. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12642-4 · Cited by 28
Contentti, E. C., López, P. A., Criniti, J. M., Pettinicchi, J. P., Cristiano, E., Patrucco, L., Contreras, E. B., Gómez‐Figueroa, E., Flores-Rivera, J. D. J., Díaz, E. P. C., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104611 · Cited by 24
Sahraian, M. A., Azimi, A., Navardi, S., Rezaeimanesh, N., & Moghadasi, A. N. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102245 · Cited by 24
“According to statistics, only 20% of patients normally needed hospitalization (Damato et al., 2016), while in case of patients with NMOSD in the current study, this rate was 60%.”
BackgroundAungsumart, S., Youngkong, S., Dejthevaporn, C., Chaikledkaew, U., Thadanipon, K., Tansawet, A., Khieukhajee, J., Attia, J., McKay, G. J., & Thakkinstian, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1166490 · Cited by 25
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders
Duchow, A. S., Paul, F., & Bellmann–Strobl, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1749259 · Cited by 21
Lai, Q., Zhang, Y., Cai, M., Zheng, Y., Qiao, S., Fang, G., & Shen, C.-H. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211054157 · Cited by 21
Wang, H., Zhou, J., Li, Y., Wei, L., Xu, X., Zhang, J., Yang, K., Wei, S., & Zhang, W. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211056710 · Cited by 21
Immunobiology of neuromyelitis optica spectrum disorders
Cuervo, D. L. M., Hansel, G., & Sato, D. K. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102618 · Cited by 21
Rituximab for people with multiple sclerosis
Filippini, G., Kruja, J., & Giovane, C. D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013874.pub2 · Cited by 22
Emerging drugs for the treatment of neuromyelitis optica
Duchow, A. S., Chien, C., Paul, F., & Bellmann–Strobl, J. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1803828 · Cited by 20
Rituximab in neuromyelitis optica spectrum disorders: Our experience
Singhal, B. S., Jade, J., & Bansi, S. (2017) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_499_16 · Cited by 20
Deng, B., Yu, H., Liu, X., Xue, Y., Zhang, X., Li, X., Yang, W., Dong, S., Qiu, Y., & Chen, X. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.02.008 · Cited by 19
Yin, Z., Qiu, Y., Duan, A., Fang, T., Chen, Z., Wu, J., Wang, Z., & Chen, G. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11641-1 · Cited by 20
Metadata
- Authors
- Damato, V., Evoli, A., & Iorio, R.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Don Carlo Gnocchi Foundation (IT)
- Corresponding author
- Iorio, Raffaele
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 73
- Issue
- 11
- Pages
- 1342
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2524675862
- Cited by
- 290
- References
- 66
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 25 · 2023: 29 · 2022: 34 · 2021: 50 · 2020: 49 · 2019: 24 · 2018: 20 · 2017: 11 · 2016: 1
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- neuromyelitis optica spectrum disorder, rituximab, CD20, off-label drug use, aquaporin-4 antibodies, annualized relapse rate, Expanded Disability Status Scale, disability progression, treatment safety, disease duration, predictors of treatment response, autoimmune demyelinating disease, B-cell depletion therapy, relapse prevention
- MeSH terms
- Rituximab, Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunologic Factors, Male, Middle Aged, Neuromyelitis Optica, Outcome Assessment, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
